Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients

• Published in: Journal of thrombosis and thrombolysis Vol. 38; no. 2; pp. 127 - 136
• Main Authors: Wagner, Henrik, Angiolillo, Dominick J., ten Berg, Jurrien M., Bergmeijer, Thomas O., Jakubowski, Joseph A., Small, David S., Moser, Brian A., Zhou, Chunmei, Brown, Patricia, James, Stefan, Winters, Kenneth J., Erlinge, David
• Format: Journal Article
• Language: English
• Published: Boston Springer US 2014; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Blood Platelets - metabolism; Body Weight; Cardiac and Cardiovascular Systems; Cardiology; Cardiology and Cardiovascular Disease; Clinical Medicine; Clopidogrel; Female; Hematology; Humans; Kardiologi; Kardiologi och kardiovaskulära sjukdomar; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Middle Aged; Pharmacodynamics; Pharmacokinetics; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - pharmacokinetics; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacokinetics; Clopidogrel; Pharmacodynamics; Pharmacokinetics; Body weight

Body weight is a predictor of clopidogrel response. However, no prospective studies have compared pharmacodynamic (PD) and pharmacokinetic (PK) data based on body weight. We compared PD and PK effects of clopidogrel 75 mg in low body weight (LBW, <60 kg) and higher body weight (HBW, ≥60 kg) patie...